MannKind doubles revenues from inhalable insulin Afrezza

You are here: Home > Central Coast Health Watch > Current Article

MannKind doubles revenues from inhalable insulin Afrezza

By Staff Report / Thursday, August 2nd, 2018 / Comments Off on MannKind doubles revenues from inhalable insulin Afrezza

MannKind reported $3.8 million in revenue from its inhalable insulin product Afrezza in the second quarter of 2018, more than double its revenue for the same period in 2017. The Westlake Village-based biotech company reported a net loss of $22.7 million, or 16 cents per share, compared to $35.3 million for the previous second quarter.…

This article is only available to Business Times subscribers

Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
Check the STATUS of your Subscription Account.